CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis
Metrics: PDF 1239 views | HTML 2050 views | ?
Zihang Chen1,3,*, Pujun Guan2,3,*, Tong Shan4, Yunxia Ye1, Limin Gao1, Zhi Wang1, Sha Zhao1, Wenyan Zhang1, Li Zhang3, Ling Pan3 and Weiping Liu1
1Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
2Huaxi Magnetic Resonance Research Center, Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
3Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
4Institute of Public Health, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
*These authors contributed equally to this work
Li Zhang, email: Li.Zhang201101@gmail.com
Weiping Liu, email: email@example.com
Keywords: CD30; extranodal natural killer/T-cell lymphoma; prognostic value; meta-analysis
Received: July 13, 2017 Accepted: January 02, 2018 Epub: January 08, 2018 Published: March 27, 2018
Background: The paradoxical reports about the prognostic value of the CD30 expression in extranodal NK/T-cell lymphoma (ENKTL) have restricted its further applications in clinical practice. To identify the common effects and the variation, we conducted this systematic review and meta-analysis.
Methods: PubMed, MEDLINE, Embase, and Web of Science were searched between January 1975 and 31 January 2017. The pooled hazard ratio was used to estimate the effect of the CD30 expression on overall survival. Bias was assessed by prespecified criteria referring to Reporting Recommendations for Tumor Marker Prognostic Studies and Newcastle-Ottawa Scale.
Results: Ten retrospective cohort studies with 310 patients are included. CD30 is associated with better overall survival significantly (HR 0.71, 95% CI 0.51 to 0.99, I2 = 0%). A greater effect is observed among studies including participants predominant in regional involvement (HR 0.31, 95%CI 0.13 to 0.76, I2 = 0%) compared with those in systemic involvement.
Conclusions: This study indicates that the CD30 expression is significantly associated with better prognosis in ENKTL, especially for patients with regional lymphoma involvement.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.